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Effect of Wilms tumor histology on response to neoadjuvant chemotherapy
Wilms tumor is often large and fragile. Consequently, large tumors are prone to rupture during surgery [1, 2] . Preoperative chemotherapy is systematically used in The International
Society of Pediatric Oncology (SIOP) and United Kingdom Children's Cancer Study Group (UKCCSG) treatment protocols and, in the case of inoperable tumors, by others too [3] [4] [5] .
Following preoperative chemotherapy, the tumor size often shrinks enabling a safer operation with a decreased risk for tumor rupture [6] . In addition, the down-staging of the tumor with preoperative chemotherapy has been suggested to spare 20% of the patients from radiotherapy or doxorubicin by UKW-3 study [7] . In a previous SIOP-9 study, tumors with stromal or epithelial predominance after chemotherapy had reduced less in volume than the tumors with necrotic, regressive or blastemal predominance [8] . However, association between pre-chemotherapy histology and tumor volume change during chemotherapy has not been investigated in detail previously.
To confirm diagnosis and to direct the most appropriate neoadjuvant regimen according to histology, cutting needle biopsy (CNB) has been used at diagnosis in our center as well as in some other centers [9] [10] [11] [12] . This allows us to compare the histological findings of the primary biopsy to the tumor volume changes during the preoperative chemotherapy, which is the primary goal of our study. In addition, we evaluated the association between postchemotherapy findings and the effect of the length of preoperative chemotherapy to the tumor volume change. Our hypothesis is that prechemotherapy histology has impact on the tumor response.
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Methods
Data source and subjects
The study cohort was identified by a retrospective review of the surgical database for patients We excluded six patients whose pathology slides could not be found for re-evaluation and five patients with a non-Wilms tumor. An additional seven patients were excluded due to lacking either pre-or postchemotherapy CT-or MRI-images. Accordingly, we included to the final analysis all the 52 Wilms tumor patients who had both original preoperative CNB and the histological samples from nephrectomy available as well as CT-or MRI-images from both before and after chemotherapy. The pathology slides were reevaluated by an experienced pathologist (JL) to confirm the diagnosis and to classify the response to preoperative chemotherapy according to current guidelines [13] . The structured histological evaluation included the estimation of the degree of necrosis (necrotic= 100%
A C C E P T E D M A N U S C R I P T 6 necrosis, regressive= 66-99% necrosis, poor response= necrosis <66%), proportions of the cellular components of Wilms tumor (epithelial, blastemal, stromal) were expressed as a percent of the total surface area of the viable tissue of the tumor, and the presence of anaplasia (focal or diffuse) [13] . Operative staging of the tumors was done by SIOP WT 2001 staging criteria [13] . Images were re-evaluated by a radiologist (OL) for the exact tumor volumes with ellipsoid formula (0.523 x a x b x c) [14] . Viable tumor volume in nephrectomy specimen was calculated by reducing the proportion of necrotic tumor (determined from histologic sample) from actual tumor volume in imaging study. At diagnosis the whole tumor was considered to be viable.
Chemotherapy regimen
The chemotherapy regimen used preoperatively was based on dactinomycin and vincristine for 2 weeks -3 months intensified with alkylators or anthracycline in patients with metastases or biopsy showing either anaplasia or in the early series if the histology was composed mostly of blastemal cells. [15] The length of chemotherapy was often increased from the standard one month if the reduction of tumor volume was considered insufficient, especially in the early series.
Statistical analysis
The association between different cellular components on CNB and the degree of necrosis or reduction in tumor volume was evaluated with Spearman correlation. The change in tumor volume was evaluated with Wilcoxon signed rank test. Continuous variables are expressed as medians and interquartile ranges (IQR) or ranges. For the analyses Statview ® 5.0.1, SAS Institute Inc. was used. P-value <0.05 was considered significant.
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Results
Patient characteristics
Twenty-three of the 52 patients were male. The median age at diagnosis was 3.4 years (IQR 2.0-5.0). The tumor was located on the right or left side, or bilateral in 28 (54%), 21 (40%) and three (6%) patients, respectively. In the cases of bilateral tumor, only the larger tumor was evaluated.
Histology of the specimens
The proportion of blastemal, stromal and epithelial components in the diagnostic CNB were 
Change in tumor volume
The median tumor volume at diagnosis was 583 ml (IQR 368-903) and the greatest dimension was 127 mm (IQR 99-144). The median volume change during the preoperative chemotherapy was -68% (IQR-85--40, range -98-+265, p<0.001). The more the tumor volume reduced during the preoperative chemotherapy, the larger the tumor necrosis was in the nephrectomy specimen (Rho=-0.502, p<0.001, Fig. 1 ). In two cases, tumor volume did not decrease despite of complete or near complete tumor necrosis. In three patients, the tumor volume increased more than 10% during the preoperative chemotherapy (Fig. 2) . Two
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8 of them had anaplastic tumor (increase in tumor volume 26 and 265%) and the third showed stromal predominance in the nephrectomy specimen (volume increase 34%).
The proportion of blastemal component in CNB correlated with the reduction in tumor volume during the preoperative chemotherapy (p=0.002, Fig. 3) . Accordingly, the higher the content of stromal or epithelial component in the CNB, the less was the reduction in tumor volume (p=0.053 and p=0.038 respectively).
When the degree of tumor necrosis and the change in tumor volume were combined the actual decrease in viable tumor volume was in median 97% (IQR 65-100) and the reduction could be seen in all cellular components (99% (IQR 93-100) in blastemal, 98% (IQR 55-100) in stromal and 85% (IQR 27-99) in epithelial component). In nine patients treated with 2-3-months' preoperative chemotherapy, CT or MRI images were available also after 4-6-weeks' chemotherapy. In six of them tumor shrank more than 10%, the tumor size remained unchanged in one patient and in two patients (one with anaplastic tumor and the other with stromal type tumor) the tumor grew with prolonged chemotherapy.
Discussion
The median reduction in Wilms tumor volume was 68% with pre-operative chemotherapy. A high proportion of blastemal cells in diagnostic CNB was associated with a significant decrease in Wilms tumor volume, whereas high percentage of stromal or epithelial cells was associated with poor reduction in tumor volume during the pre-operative chemotherapy.
However, the actual viable volume of all these three components decreased during the A C C E P T E D M A N U S C R I P T 9 chemotherapy. Tumor growth was rare during the pre-operative chemotherapy and it was associated with diffuse anaplasia in two of the three cases.
In previous studies evaluating the effect of preoperative chemotherapy on tumor volume no comparisons were made to prechemotherapy histology in contrast to our study. In SIOP-9 study with 1052 patients, the median tumor volume reduction was 62% with preoperative chemotherapy [16] . An increase in tumor volume was observed in 12% of the patients. In SIOP-9 /GPOH study, analyzing the association between tumor histology in nephrectomy samples and the change in tumor volume during preoperative chemotherapy, more than 40% of decrease in volume was common in necrotic, regressive, mixed or blastemal type tumor in nephrectomy specimens but rare in epithelial and stromal type tumors [8] . Our results are in accordance with those results. In a cohort of patients treated in UKW-3 study, all five high risk tumors reduced in tumor volume (in median by 79%). However, among patients belonging to intermediate risk group (epithelial, stromal, regressive or focal anaplasia type in nephrectomy specimen) only 10/15 had reduction in tumor volume whereas 5/15 had increase in tumor volume [17] . Similarly, in a study from Belgium, in which most tumors belonged to the intermediate group, the mean reduction of tumor volume was 61% in 12/17 cases, whereas in the remaining five cases tumor volume increased in mean by 43% [18] . When applying the UK study risk classification criteria to our study, six high risk tumors with blastemal predominance after chemotherapy had comparable decrease in tumor volume as in the UK study. However, in contrast to the UK study, both tumors with diffuse anaplasia in our series were chemoresistant and grew despite the use of preoperative chemotherapy.
Furthermore, in our study only one (stromal type) of 42 intermediate risk tumors continued to grow despite of chemotherapy.
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